Since the IFNα/β receptor inhibitor anifrolumab suggested improvements to primary or secondary outcomes in SLE [33, 34], it will be interesting to see whether RA patients with high IFNα protein level may benefit from this medication. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.